Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P900009/S050

SONIC ACCELERATED FRACTURE HEALING SYSTEM MODEL 2A

Bioventus, LLC · Decision date Mar 6, 2026

FDA DECISIONP900009/S050

What did the FDA decide?

FDA records P900009/S050 as a supplement to PMA P900009, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 6, 2026.

FDA approval order statement

a change in the manufacturing facility associated with the transducer cable assembly for the EXOGEN Ultrasound Bone Healing System.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Orthopedic
Decision date
Mar 6, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P900009/S050
Regulatory pathway
PMA supplement
Product code
LOF
Decision code
OK30
Decision date
Mar 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, bone growth, non-invasive.

Product code
LOF
FDA device class
2

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P900009/S050 received

    Application receipt date recorded by FDA.

  2. P900009/S050 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P900009. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code LOF

Product / regulatory recordCompanyPathwayDecision dateSource
Djo, LLC510(k) clearanceSep 29, 2026FDA
ActaStim-SP190030/S004
Theragen, Inc.PMA supplementMay 13, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Bioventus, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
4721 Emperor Blvd., Suite 100, Durham, NC, 27703

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records